INTERNATIONAL PATENT: BIONTECH SE, MEDILINK THERAPEUTICS (SUZHOU) CO., LTD. FILES APPLICATION FOR "USE OF ANTI-HER3 ANTIBODY-DRUG CONJUGATES IN CANCER TREATMENT"

GENEVA, Dec. 9 -- BIONTECH SE (An der Goldgrube 1255131 Mainz), MEDILINK THERAPEUTICS (SUZHOU) CO., LTD. (Unit 101, Block B3, Biotech Industrial Park218 xinghu Street, Suzhou Industrial ParkSuzhou Area of China (Jiangsu)Pilot Free Trade ZoneSuzhou, Jiangsu 215000) filed a patent application (PCT/EP2025/064957) for "USE OF ANTI-HER3 ANTIBODY-DRUG CONJUGATES IN CANCER TREATMENT" on May 29, 2025. With publication no. WO/2025/248072, the details related to the patent application was published on Dec 04, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): XUE, Tongtong (C/O Medilink Therapeutics (Suz...